Pharmamarketeer

EMA committee recommends approval of Merck’s Zerbaxa 3g dose to treat adults with HAP, including VAP

Merck, known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Zerbaxa 3g dose

Medhc-fases-banner
Advertentie(s)